The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
April 29, 2024
View Complete Issue         Table of Contents 2019 
Lifileucel (Amtagvi): A Cellular Therapy for Melanoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lifileucel (Amtagvi): A Cellular Therapy for Melanoma (online only)
April 29, 2024 (Issue: 1701)
Lifileucel (Amtagvi – Iovance), a tumor-derived autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic melanoma previously treated with a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lifileucel (Amtagvi): A Cellular Therapy for Melanoma (online only)
Article code: 1701h
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.